IRG1-IN-1

Research use only, not for human use.

IRG1-IN-1, an itaconic acid derivative, inhibits Immune Response Gene 1 (IRG1) activity and is suitable for cancer, inflammation, and autoimmune disease research.

IRG1-IN-1 is an itaconic acid derivative. IRG1-IN-1 can inhibit immune-responsive gene 1 (IRG1) activity. IRG1-IN-1 can be used for the research of cancer, inflammation and autoimmune diseases.

IRG1-IN-1(compound 6) (0.5 mM; 2 mM) reduces production of itaconic acid and the secretion of TNFα from LPS-stimulated human monocyte derived macrophages (hMDMs) .IRG1-IN-1 (0.5 mM; 1 mM) inhibits the proliferation of C-IRG1-9 rat glioma cells.IRG1-IN-1(10 nM) increases proliferation of TCR-activated hCD8+ T cells.IRG1-IN-1(10μM) shows depletion of trimethylation of histone 3 at lysine 4 (H3K4me3) in CR-activated hCD8+ T cells.Western Blot Analysis Cell Line:TCR-activated hCD8+ T cells Concentration:10 μM Incubation Time:24-72 h Result:Decreased protein levels of histone 3 (H3).Cell Proliferation Assay Cell Line:C-IRG1-9 rat glioma cells and TCR-activated hCD8+ T cells Concentration:0.5 mM; 1 mM; 10 nM Incubation Time:48-96 h Result:Inhibited the proliferation of C-IRG1-9 rat glioma cells and increased proliferation of TCR-activated hCD8+ T cells.

IRG1-IN-1 (compound 6) (i.p.; 0.2 mg/kg; 27 days) shows antitumor effect in C57BL/6 mice.Animal Model:C57BL/6 mice Dosage:0.2 mg/kg Administration:IP; 27 days Result:Increased survival of C57BL/6 mice bearing mouse CT26 colorectal tumors.Decreased intratumoral frequency of M-MDSCs in tumors.

——

Others

Other Targets

Others

——

——

2407652-42-8

314.31

C18H15FO4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (318.16 mM; Ultrasonic )

O=C(O)C(=CC1=CC=C(F)C=C1)C(C(=O)O)CC=2C=CC=CC2

——

(-20℃)

With Ice Pack

≥ 2 years